The main indications are: -premature contractions, -hemorrhage during pregnancy, -conditions of fetal distress, -maternal diseases. Predominant among the four main indications is the respiratory distress symdrome prophylaxis in cases of imminent premature birth. Cases of a imminent or expected premature birth frequently requires tocolysis, which involves particular problems in connection with the glucocorticoid treatment. Here it must be clarified whether the combination of tocolysis and glucocorticoid therapy does not lead to an unjustifiable endangering of the mother. Hemorrhage during pregnancy as the indicator of an atypical placenta insertion must always be interpreted as a potential premature or early delivery risk. By conditions of fetal distress, we mean the few cases with fetal distress which still permit temporal prolongation of the delivery until the corticoid effect has been attained. There also frequently include multiple pregnancies, where delivery is usually before them. Increasingly rare are the cases that require premature delivery for early extrauterine therapy in the fetus, as, for instance, rhesus incompatibility or surgically correctable fetal anomalies. Maternal indications for premature delivery are extremely rare in Europe and also in the United States.
We regard the following as absolute or relative contraindications:
-severe forms of preeclampsia, -diabetes mellitus, -premature rupture of membranes, -maternal and/or intrauterine infections.
In our opinion, the combination of tocolysis and glucocorticoid therapy demands intensive medical surveillance, above all, strict balancing of the water equilibrium and electrolyte metabolism. Tocolysis may cause retardation of surfactant synthesis [5] . The combination with glucocorticoids appears useful. WOLFF [15] was able to clearly demonstrate by cardiac catheter examination that the pulmonary vascular resistance cannot be considered as causal for intrapulmonary pressure increase and tendency towards edema formation, which is a possible risk under the combination therapy with tocolysis and glucocorticoids. LIGGINS [9] already emphasized in 1976 that eclampsia and preeclampsia must be regarded as a contraindication for steroid therapy. LAMONT and co-workers [7] , on the other hand, saw advantages for the fetus in a glucocorticoid therapy even in the presence of severe hypertension. In any case, careful consideration is necessary in carrying out such therapy in this group of patients. If such therapy is used, strict intensive medical precautions must be taken. Otherwise, the therapy is rejected because of the high intrauterine mortality rate of the fetuses in the course of the basic disease and, in connection with a combina-tion therapy with tocolytics, because of the known danger of pulmonary edema. In our opinion, severe preeclampsia does not, as a rule, permit the application of a lung maturation treatment, because, with this clinical picture, it is usually of primary importance to terminate the pregnancy as quickly as possible.
RDS prophylaxis in diabetics is controversial, although it has been considered justifiable [14] . Under the steroid therapy, we observed attacks of fever above 38.5 degrees in 7 of 27 diabetic women and, in 5 of 27, serious alterations in the glucose level and insulin requirement. Despite intensive medical treatment, one of 27 patients died of a severe pulmonary Klebsiella infection with artificial respiration.
Premature rupture of the amnion is thought to lead, via fetal stress, to an increased endogenous glucocorticoid production which in its turn reduces the incidence of RDS. In any case, BERKOWITZ [2] was able to demonstrate a decrease of RDS cases as well as an increase in the L/S ratio after premature rupture of the amnion if this happened earlier than 16 or 24 hours in pregnancies before the 32nd week of pregnancy. We proceed at our clinic according to the following scheme (table I).
Intrauterine infections do not as a rule permit a continuation of the endangered pregnancy.
TAESCH et al [13] point out the connection between glucocorticoid treatment and a doubling of the maternal and neonatal infection risk, particularly if the premature rupture of the amnion happened a long time before.
There are also reports to the contrary [4]. We consider it possible to perform antibiotic therapy in the mother after premature rupture of the amnion but nevertheless view this measure as extremely problematic with regard to its effect on the fetus.
On the whole, the substances have become generally accepted in clinical practice for the performance of a prenatal lung maturation treatment. These are betamethasone and dexamethasone. Alternative therapies will be discussed later at this congress. The application schemes are shown in table II.
The usefulness of an RDS prophylaxis with glucocorticoids has been confirmed by several prospective studies in the past. All investigations demonstrate a marked reduction of the RDS frequency (table III ). An RDS prophylaxis should be weighed against the possible risks as a matter of principle in cases where a premature birth is to be expected. In this connection, the indication should be established all the earlier, the more immature the expected premature infant will be. Detailed results are available from the Collaborative Group on Antenatal Steroid Therapy [3]. Accordingly, a particularly marked advantage is recognizable for singleton pregnancies with a reduction of RDS incidence from 18 to 12.6%. Female fetuses profit in a very particular way (table IV) .
The often discussed negative effects on neonatal development, particularly of the brain, have not been confirmed [1, 11, 16] .
Our own results are presented on the basis of 637 non-randomized cases from the years 1980 to 1985. In about one third of our cases, an RDS prophylaxis was carried out in underweight chil- dren. In the group of untreated cases, we have fewer neonatal RDS than in the treated collective, which is already an indication of the different risk grouping. One hundred ninety-four of 637 living premature infants below 2500 g birth weight received prophylactic treatment with betamethasone. Forty-seventy infants with RDS occurred in this group. In contrast, we had only 30 infants with RDS in 443 untreated pregnancies. This is of course due to the incomparability of the collectives.
The dependence of the therapeutic result on the sex of the newborn is also substantiated by our cases. The neonatal course of 50 boys was compared with that of 45 girls weighting ^ 2000 g (appropriate for gestational age babies). The RDS incidence was significantly different in the two groups after a betamethasone prophylaxis. It was 1/25 (4%) in the girls compared to 13/31 (42%) in the boys group (table V) . If we check in our data the effectiveness of a betamethasone treatment, we see that, both in the collective of the Heidelberg University Clinic [6] and in our own cases, a marked reduction of the RDS incidence was only detectable after betamethasone therapy as of the 32nd week of pregnancy (table VI). Up to that time, nearly every second child develops a respiratory distress syndrome despite RDS prophylaxis, the severe forms of stages III and IV predominating, but after corticoid treatment a change towards less severe stages (I and II) can be shown and the mortality due to RDS (III and IV) is remarkably lower (table VII) .
Conclusions:
We recommend RDS prophylaxis for all premature contractions between the 32nd and 34th week of pregnancy inclusively. In addition, it should be given in cases of confirmed lung immaturity. Special restrictions are necessary in cases of preeclampsia, eclampsia, diabetes and confirmed maternal infections. In the group of diabetics or preeclamptic patients, an RDS prophylaxis should only be given, if at all, when it can be performed under intensive medical conditions.
Summary
Main indications for antenatal administration glucocorticoid to pregnant women are premature contractions, hemorrhage during pregnancy, conditions of fetal distress and maternal diseases. There are some absolute or relative contraindications as well: severe forms of preeclampsia, diabetes mellitus, premature rupture of membranes, maternal and/intrauterine infections. In a retrospective evaluation of the data obtained at our institution of 637 nonrandomized cases from the years 1980 -1985, we could demonstrate the dependence of the therapeutic results on the sex of the newborn. The RDS incidence is significantly different after betamethasone prophylaxis. It was 1/25 (4%) in girls compared to 13/31 (42%) in boys.
A marked reduction of the RDS incidence is only detectable after betamethasone therapy from the 32nd to the 34th week of gestation. Thus we recommend RDS prophylaxis for all patients with premature contraction, mainly between the 32nd and 34th week of pregnancy. In addition, it should be given in cases of confirmed lung immaturity. Special restrictions are necessary in cases of preeclampsia, eclampsia, diabetes and confirmed maternal infections. In the group of diabetes or preeclampsia patients an RDS prophylaxis should only be given, if at all, when it can be performed under intensive care conditions.
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